)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Edgewise Therapeutics (EWTX) investor relations material
Edgewise Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Advanced two clinical-stage programs: sevasemten for muscular dystrophies and EDG-7500 for cardiac diseases, both in Phase 2 trials as of June 30, 2025.
Achieved key milestones in muscle and cardiac programs, including positive top-line data for sevasemten in Becker and Duchenne muscular dystrophy and advancement of EDG-7500 in HCM.
Building commercial infrastructure for a potential U.S. launch of sevasemten in Becker and planning Phase 3 trials in HCM and Duchenne.
Net loss of $36.1 million for Q2 2025 and $76.9 million for the six months ended June 30, 2025; accumulated deficit reached $455.5 million.
No revenue generated to date; operations funded primarily through equity offerings and private placements.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $594.0 million at quarter-end, expected to fund operations for at least the next 12 months.
Q2 2025 research and development expenses were $33.6 million, up $2.9 million year-over-year, but down $3.2 million from the previous quarter.
General and administrative expenses for Q2 2025 were $9.1 million, up $1.6 million year-over-year, nearly flat compared to $9.2 million in the prior quarter.
Net loss for Q2 2025 was $36.1 million ($0.34 per share), compared to $40.8 million ($0.43 per share) in Q1 2025.
Net cash used in operating activities for the first half of 2025 was $70.4 million, compared to $54.7 million in the prior year period.
Outlook and guidance
Existing cash and securities expected to fund planned operating and capital expenditures through at least the next 12 months.
GRAND CANYON trial in Becker is on track for topline data in Q4 2026, with a clear FDA path to registration.
Plans to meet with FDA in Q4 2025 to discuss Phase 3 design for Duchenne and initiate pivotal study in 2026.
CIRRUS-HCM trial update expected in Q4 2025; first-in-human Phase 1 trial of EDG-15400 for heart failure to begin dosing in Q3 2025.
Substantial additional capital will be required to fund operations and development beyond the current cash runway.
Discuss Phase 3 trial design plans for Duchenne.
When will GRAND CANYON topline data be released?
What is driving the decrease in R&D expenses?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Edgewise Therapeutics earnings date
Q3 20256 Nov, 2025
Next Edgewise Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Edgewise Therapeutics Inc. (EWTX) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for severe, rare muscle disorders, addressing significant unmet medical needs. Utilizing its proprietary drug discovery platform, Edgewise focuses on targeting the muscle as an organ, combining expertise in muscle biology and small molecule engineering. This approach allows the identification of precision medicines regulating key proteins in muscle tissue. Edgewise Therapeutics is headquartered in Boulder, Colorado, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage